Pharmaceuticals
neoX Biotech closes US$30 million Series A round
BEIJING, Feb. 9, 2021 /PRNewswire/ -- neoX Biotech, a next-generation biotech company specializing in computational design for novel drug research and development, recently announced that it had raisedUS$30 million in Series A funding.The financing was co-led by Sky9 Capital and 5Y Capital (forme...
2021-02-09 21:28
3769
Regent Pacific's Strategic Partner Obtains Clinical Trial Approval for FORTACIN(TM)
HONG KONG, Feb. 9, 2021 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK), a specialist healthcare, wellness and life sciences investment group is pleased to announce that Wanbang Biopharmaceutical...
2021-02-09 20:35
8444
Nuance Pharma Announces Strategic Licensing Deal with Antibe Therapeutics in China
TORONTO and SHANGHAI, Feb. 9, 2021 /PRNewswire/ -- Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) today announced that it has licensed otenaproxesul to Nuance Pharma for commercialization in theGreater China region. Nuance is a biopharmaceutical company focused on licensing, developing and com...
2021-02-09 20:00
6095
Yingli Pharma and Hengrui Medicine Reach a Strategic Agreement to Jointly Explore the Oncology Market in China
SHANGHAI, Feb. 9, 2021 /PRNewswire/ -- Yingli Pharma announced today that it reached strategic collaboration with Hengrui Medicine (600276.SH), a partnership which will significantly accelerate the expansion of Yingli Pharma's oncology business inChina, the second largest pharmaceutical market in...
2021-02-09 08:30
2343
The World's Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics
* Greatly increase the company's current capacity to 90,000L and enable WuXi Biologics to initiate any project within four weeks * Offer flexible large-scale manufacturing services by implementing Scale-out strategy WUXI, China, Feb. 9, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.H...
2021-02-09 08:25
2957
Innovent Announces First Patient Dosed in Phase III Pivotal Trial of IBI310 (CTLA-4) Combined with TYVYT® (sintilimab injection) for the Treatment of First-line Advanced Hepatocellular Carcinoma
SAN FRANCISCO and SUZHOU, China, Feb. 9, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major dis...
2021-02-09 08:00
9003
Inova Appoints Claude Basset as Chief Product Officer
LYON, France, Feb. 8, 2021 /PRNewswire/ -- Inova, the market-leading partnering platform for the pharmaceutical and biotech industry, today announced that Claude Basset has joined their leadership team as Chief Product Officer. Inova is a French Tech success story that, now in its 10th year, ha...
2021-02-08 16:00
1631
Orpha Labs AG Initiates Compassionate Use Program for ORL-101 in Leukocyte Adhesion Deficiency Type II (LAD-II)
First Patient to Receive ORL-101 in Israel This Week BAAR, Switzerland, Feb. 8, 2021 /PRNewswire/ -- Orpha Labs AG today announced its compassionate use program to make ORL-101 available to physicians providing care for Leukocyte Adhesion Deficiency Type II (LAD-II) patients. ORL-101 is a novel ...
2021-02-08 15:00
3455
Sihuan Pharmaceutical (0460.HK) The sole agent of Letybo 100U China AI Listing Conference was successfully held
HONG KONG, Feb. 5, 2021 /PRNewswire/ -- Exclusively represented by Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460), Letybo®100U, a type A botuli...
2021-02-05 11:32
6548
Global survey presented at the Digital Liver Cancer Summit 2021 reveals heavy toll of COVID-19 first wave on liver cancer care
GENEVA, Feb. 5, 2021 /PRNewswire/ -- The delays of screening programmes, diagnostic imaging and biopsies, cuts in the numbers of physicians available to treat liver cancer patients, cancellations of surgery, and a drop in the number of patients entered on clinical trials, were just some of the is...
2021-02-05 07:00
2947
Covid-19 Drug Duo Achievements: GoldenBiotech's New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries
TAIPEI, Feb.4, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132)("GoldenBiotech"), a leading Taiwanese biopharmaceutical company, announced that it has made two achievements for its Covid-19 new drug candidate Antroquinonol® (HOCENA®): receiving positive response after DMC review in Pha...
2021-02-04 20:30
2053
Vemlidy(r) Demonstrates Continued Efficacy and Improved Safety for Asian Patients with Hepatitis B
SINGAPORE, Feb. 4, 2021 /PRNewswire/ -- Gilead Sciences announced today at the 2021 Asian Pacific Association for the Study of the Liver Conference (APASL), findings from two sub-analyses that demonstrated the continued efficacy and improved safety of Vemlidy® (tenofovir alafenamide 25 mg, TAF) ...
2021-02-04 12:00
5091
FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations
Not intended for distribution in the USA, Canada or UK - TEPMETKO is approved for both treatment naïve and previously treated MET ex14 positive NSCLC patients - TEPMETKO demonstrated consistent and durable responses in both treatment naïve and previously treatedMETex14 patients in the VISION stud...
2021-02-04 02:57
1889
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...
2021-02-03 12:30
10150
Elekta's MOSAIQ and Versa HD earn top honors in 2021 Best in KLAS: Software and Services Report
ATLANTA, Feb. 3, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced that itsMOSAIQ® Oncology Information System (OIS) and Versa HD™ linear accelerator have been named "Best in KLAS" in the 2021 Best in KLAS: Software and Services Report. MOSAIQ was ranked first in the Oncology (Radiation) ca...
2021-02-03 00:30
3967
Kira Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial for P014, a Bifunctional Biologic Medicine
CAMBRIDGE, Mass. and SUZHOU, JIANGSU, China, Feb. 2, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, announced today that the first healthy volunteer has been successfully dos...
2021-02-02 20:00
2213
Ascentage Pharma Released Preclinical Results of MDM2-p53 Inhibitor APG-115 in an Oral Presentation at WCLC 2020, Demonstrating Therapeutic Potential in STK11-Mutant Non-Small Cell Lung Cancer
SUZHOU, China and ROCKVILLE, Md., Feb. 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the company recently released ...
2021-02-02 17:24
2344
Globally unique MRI Guarantee: The highest MRI safety with hearing implants from MED-EL
Worry-free, safe magnetic resonance imaging (MRI) with MED-EL cochlear, middle ear or bone conduction implants – now with lifetime guarantee. For immediate access to an MRI examination without surgery, discomfort or hearing downtime. INNSBRUCK, Austria, Feb. 2, 2021 /PRNewswire/ -- The innovative...
2021-02-02 15:00
3202
Inmagene launched U.S. subsidiary; Dr. Jean-Louis Saillot joined the company.
SAN DIEGO, Calif. and SHANGHAI, Feb. 2, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a leading biotech company focused on immunology-related therapeutic areas, today announced the launch of its wholly-owned subsidiary inSan Diego. Jean-Louis Saillot, MD has joined the company a...
2021-02-02 14:48
3242
CF PharmTech and Chengdu Shangyi Launch the "Home-Based Recovery Program for Discharged Covid-19 Patients" and Announce Today's Global Release of the "R Plus Health" Free App
SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- CF PharmTech, Inc. is a fully
integrated pharmaceutical company inChina specializing in the treatment of
respiratory diseases. Chengdu Shangyi Information Technology Co., Ltd is a
professional IT service company in the healthcare industry inChina.
2021-02-02 09:00
3742
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
Asia Pacific Defies Global Headwinds: Mastercard Economics Institute 2026 Outlook
[Picked up by 277 media titles]
2025-12-10 09:00